THE ARROVEN STUDY (MA25101): POST-AUTHORISATION OBSERVATIONAL SAFETY STUDY OF BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA

  • Kim Linton (Other)

Activity: Internal positions, career professional development, other peer review and other › Other › Research

Description

I am the UK co-ordinating investigator for this international phase 4 clinical trial
PeriodMar 2013 → Dec 2018
Held atTakeda Oncology, United States, Massachusetts
Degree of RecognitionInternational

Keywords

  • Brentuximab vedotin
  • safety
  • Hodgkin lymphoma
  • Anaplastic Large Cell Lymphoma

Related content